Candel Therapeutics highlights $201.6 million in cash and cash equivalents as of June 30, 2026, with expected runway into 2028. Investors also get updated clinical and financing markers, including positive phase 3 prostate cancer data, positive survival results in two cancers, and facilities totaling up to $130 million and $100 million.
Key Highlights
- Aglatimagene has been administered to more than 1,000 patients, with nearly 50% tumor-volume reduction reported in one NSCLC patient over three weeks.
- Aglatimagene besadenovec (CAN-2409) is described as an off-the-shelf therapy for pan-solid tumors designed to generate an individualized anticancer immune response.
- Linoserpaturev (CAN-3110) is an investigational oncolytic HSV-1 program designed for tumor-specific replication.
- Candel reports positive overall survival data from phase 2a studies and expected cash runway into 2028.
Its September 2026 investor presentation highlights clinical progress for aglatimagene besadenovec and linoserpaturev, two programs designed to support cancer treatment development.
$130M Loan and $100M Royalty Agreement
Aglatimagene besadenovec, also known as CAN-2409, is described as an off-the-shelf therapy for pan-solid tumors that aims to generate an individualized anticancer immune response. The program has been administered to more than 1,000 patients and has received several regulatory designations across prostate cancer, non-small cell lung cancer and pancreatic cancer. Linoserpaturev, or CAN-3110, is an investigational oncolytic HSV-1 program designed for tumor-specific replication.
Clinical Data Supports 2028 Cash Runway
It also reports positive overall survival data from phase 2a studies in borderline resectable pancreatic cancer and therapy-resistant non-small cell lung cancer. A single non-small cell lung cancer patient treated with aglatimagene showed nearly 50% lower tumor Volume over three weeks. Candel (NASDAQ: CADL) also cites proof of concept for linoserpaturev in recurrent high-grade glioma, while its cash balance is described as providing expected runway into 2028.
FAQs
Q: How much cash does Candel Therapeutics have?
A: Candel Therapeutics reported $201.6 million in cash and cash equivalents as of June 30, 2026. The presentation says that balance provides expected runway into 2028.
Q: What clinical progress did Candel Therapeutics highlight?
A: The presentation cites a positive phase 3 prostate cancer trial for aglatimagene and positive overall survival data from phase 2a studies in pancreatic cancer and NSCLC.
Q: What financing items are highlighted?
A: It also says Candel’s cash balance is expected to provide runway into 2028.
Q: What is aglatimagene besadenovec designed to do?
A: Aglatimagene besadenovec, also known as CAN-2409, is described as an off-the-shelf therapy for pan-solid tumors. It aims to generate an individualized anticancer immune response.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.